| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 11/12/2008 | CN100432070C Novel sulfamides and their use as endothelin receptor antagonists |
| 11/12/2008 | CN100432055C Tricyclic protein kinase inhibitors |
| 11/12/2008 | CN100432049C Cycloalkene derivatives, process for producing the same and use |
| 11/12/2008 | CN100431591C Method for preparing extractive of corn leaves |
| 11/12/2008 | CN100431573C Medicine for treating aurigo |
| 11/12/2008 | CN100431555C Dioxin elimination promoter |
| 11/12/2008 | CN100431553C Composition for improving obstacle under pharynx |
| 11/12/2008 | CN100431542C Application of yohimbine and berberine mixture in medicament preparation |
| 11/12/2008 | CN100431434C Soft drink replacer |
| 11/11/2008 | US7449583 Process for the preparation of 4-(8-chloro-5 6-dihydro-11h-benzo-(5 6)-cyclohepta-(1 2b)-pyridin-11-ylidene-1-piperidiniecarboxylic acid ethyl ester (loratadine) |
| 11/11/2008 | US7449559 deletion of residues in the CR2 domain of the EGFR ectodomain gives rise to a truncated ectodomain with enhanced affinity for epidermal growth factors such as (EGF) and/or transforming growth factor-I (TGF- alpha ); psoriasis and tumor states |
| 11/11/2008 | US7449548 Nucleic acid and corresponding protein entitled 193P1E1B useful in treatment and detection of cancer |
| 11/11/2008 | US7449537 Antineoplastic polyalkoxyalkylsiloxanes and methods of use thereof |
| 11/11/2008 | US7449495 e.g. 4-(3-(1-Adamantyl)-4-tert-butyldimethyl-silyloxyphenyl)benzaldehyde; antitumor, antiinflammatory agent; arthritic pathology, metastatisation, diabetic retinopathy, psoriasis, chronic inflammatory disease, and atherosclerosis; sarcoma, carcinoma, carcinoid, leukaemia |
| 11/11/2008 | US7449493 N-[2-[[1-[[[(2,4-dimethylphenyl)methyl]amino]methyl]cyclohexyl]amino]-2-oxoethyl]-3-(trifluoromethyl)benzamide; monocyte chemoattractant proteins receptor antagonists or partial agonists/antagonists; antiinflammatory agent, autoimmune diseases; rheumatoid arthritis, multiple sclerosis, atherosclerosis |
| 11/11/2008 | US7449492 Therapeutic agents—I |
| 11/11/2008 | US7449490 Pharmaceutically active compounds and methods of use |
| 11/11/2008 | US7449482 Piperidine compounds useful as malonyl-CoA decarboxylase inhibitors |
| 11/11/2008 | US7449479 Hepatitis C virus inhibitors |
| 11/11/2008 | US7449475 e.g. 2-{[(2S)-3-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}-N-cyclopropylbenzamide; macrophage inflammatory protein (MIP)-1 alpha chemokine receptor modulator; antiinflammatory, antiproliferative agent, autoimmune diseases |
| 11/11/2008 | US7449472 Methods of inhibiting p38 with substituted bicyclic pyrimidines |
| 11/11/2008 | US7449466 Cyclic aminophenyl sulfamate derivative |
| 11/11/2008 | US7449456 signal transducer and activator of transcription-6 inhibitors; asthma, COPD, respiratory, inflammatory and allergic diseases; compounds have less suppressive effect on immunological functions; 4-[(2,5 -difluorobenzyl) amino]-2-[(4-morpholin-4-ylphenyl)amino]pyrimidine-5 -carboxamide |
| 11/11/2008 | US7449450 Compounds, methods of screening, and in vitro and in vivo uses involving anti-apoptotic genes and anti-apoptotic gene products |
| 11/11/2008 | US7449446 Synergistic mixture; anticoagulants |
| 11/11/2008 | US7449177 administering to gamma-interferon, in combination with antihistamines, antiallergens, corticosteroids or mixtures, for the treatment of autoimmune skin diseases; suppression of chemotaxis and function of eosinophils |
| 11/11/2008 | US7449176 Treatment of inflammatory bowel disease with IFN-γ inhibitors |
| 11/11/2008 | US7449175 Delivery of erectile dysfunction drugs through an inhalation route |
| 11/11/2008 | US7449174 Delivery of analgesics through an inhalation route |
| 11/11/2008 | US7449172 Delivery of antiemetics through an inhalation route |
| 11/11/2008 | US7448379 Composition, vessel, dry powder inhalation system, and related methods for transpulmonary administration |
| 11/06/2008 | WO2008133349A1 Agent for prevention of cirrhosis/precancerous lesion comprising natriuretic peptide as active ingredient |
| 11/06/2008 | WO2008133274A1 Aminodihydrothiazine derivatives substituted with cyclic groups |
| 11/06/2008 | WO2008133192A1 Fused imidazole compound and use thereof |
| 11/06/2008 | WO2008133173A1 Processed product of fenugreek seed, and method for production thereof |
| 11/06/2008 | WO2008133155A1 Bicyclic heterocyclic compound |
| 11/06/2008 | WO2008133141A1 Osmotin recombinant protein, method for production of the same, and use of the same |
| 11/06/2008 | WO2008133137A1 Vector for gene therapy |
| 11/06/2008 | WO2008133132A1 Method for improvement in activities of reactive oxygen species-scavenging enzymes |
| 11/06/2008 | WO2008133129A1 Therapeutic agent for glaucoma comprising adenosine a2a receptor agonist as active ingredient |
| 11/06/2008 | WO2008133127A1 Fused heterocyclic derivative, pharmaceutical composition comprising the derivative, and use of the composition for medical purposes |
| 11/06/2008 | WO2008133021A1 COMPOSITION FOR AMELIORATING OPTIC NERVE DISORDER COMPRISING PROSTAGLANDIN F2α COMPOUND AS ACTIVE INGREDIENT |
| 11/06/2008 | WO2008132950A1 External preparation for skin and external preparation for lips |
| 11/06/2008 | WO2008132846A1 Tricyclic heteroaryl compound |
| 11/06/2008 | WO2008132211A1 Amino-quinazolinone derivatives for use as radiotracers and imaging agents |
| 11/06/2008 | WO2008115061A3 Dual targeting system |
| 11/06/2008 | WO2008104883A8 Methods for the treatment of anal incontinence |
| 11/06/2008 | WO2008094976A3 Use of estrogen receptor beta selective ligands for treating acute lung injuries |
| 11/06/2008 | WO2008027837A3 Small molecule potentiator of hormonal therapy for breast cancer |
| 11/06/2008 | US20080275258 antilipemic agents for regulation or prevention of obesity; food and tea drink; reacting a flavan-3-ol with formaldehyde; used in smaller amounts, plant extracts; enzyme inhibitor as hypotensive agents, antidiabetic agent, aging resistance, anticarcinogenic agent |
| 11/06/2008 | US20080275127 Arylsulfonamido-substituted hydroxamic acid derivatives |
| 11/06/2008 | US20080275124 Powder of amino acids and method for producing the same |
| 11/06/2008 | US20080275123 N-halogenated amino acid formulations |
| 11/06/2008 | US20080275121 For contact lenses; surface treatment |
| 11/06/2008 | US20080275087 Biphenylcarboxamides useful as lipid lowering agents |
| 11/06/2008 | US20080275081 Novel thrombomodulin expression promoters |
| 11/06/2008 | US20080275075 Medicine Comprising a Combination of an Acetylcholinesterase Inhibitor and a 5-Substituted-3-Oxadiazolyl-1,6-Naphthyridin-2(1H)-One Derivative |
| 11/06/2008 | US20080275069 3,8-dimethyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]-4(3H)-quinazolinone; 6-chloro-3-methyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]pyrido[3,4-d]-pyrimidin-4(3H)-one; 2-[4-(1-cyclopentyl-4-piperidinyloxy)phenyl]-3-methylpyrido[2,3-d]-pyrimidin-4(3H)-one; treats metabolic, nervous system, vascular disorders |
| 11/06/2008 | US20080275059 Novel physiologically active substances |
| 11/06/2008 | US20080275033 Administering Diamino-substituted phenothiazinium compound; antimicrobial photosensitisers effective against Gram negative bacteria, Gram positive bacteria; photodynamic therapy |
| 11/06/2008 | US20080275024 Amyloid precursor protein/gamma-secretase inhibitors; amides of aminobenzodiazepines: 2-(3,5-difluorophenyl)-N {[N-(1-methyl-2-oxo-5-phenyl((S)-3H-benzo[f]1,4-diazepin-3-yl))carbamoyl]cyclohexyl}acetamide |
| 11/06/2008 | US20080275020 Pharmaceutical formulation |
| 11/06/2008 | US20080275010 Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs |
| 11/06/2008 | US20080275008 Modulate sphingosine-1-phosphate (S1P) receptors with fewer side effects; for example, 2-amino-5-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-methylpentylphosphonic acid monoester; prophylactic or therapeutic agents against rejection of organ transplants, skin grafts, rheumatoid arthritis, lupus |
| 11/06/2008 | US20080275004 N-Substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
| 11/06/2008 | US20080274980 Macromonomers and hydrogel systems using native chemical ligation, and their methods of preparation |
| 11/06/2008 | US20080274974 Process for removing viruses in fibrinogen solutions and fibrinogen obtained by said process |
| 11/06/2008 | US20080274965 Encapsulated amyloid-beta peptides |
| 11/06/2008 | US20080274964 Human Spasmolytic Polypeptide in Glycosylated Form |
| 11/06/2008 | US20080274953 Method of Preparing a Protein Aggregate and a Pharmaceutical Preparation |
| 11/06/2008 | US20080274946 Method and composition for restoration of age related tissue loss in the face or selected areas of the body |
| 11/06/2008 | US20080274506 Host cell comprising vector expressing protein fusion comprising neonatal Fc receptor for use in enhancing antibody-dependent cell-mediated cytotoxicity (ADCC) targeting of cancer cells |
| 11/06/2008 | US20080274468 Novel means for the diagnosis and therapy of ctcl |
| 11/06/2008 | US20080274194 Stabilized Hme Composition With Small Drug Particles |
| 11/06/2008 | US20080274188 Oral Vehicle For Systemic Pharmaceuticals |
| 11/06/2008 | US20080274177 Monolithic coating comprising aqueous dispersion of neutral acrylic ester copolymer without any functional groups and polyglycol; short curing times; shelf life |
| 11/06/2008 | US20080274175 Compositions Comprising Edible Oils and Vitamins and/or Minerals and Methods for Making the Compositions |
| 11/06/2008 | US20080274172 Liposome Preparation Method |
| 11/06/2008 | US20080274166 Patch for Transdermal Drug Delivery |
| 11/06/2008 | US20080274161 Hydrogels and hydrogel particles |
| 11/06/2008 | US20080274158 biodegradable hydrogel FGF-beta mimetic; PEG-dihydrazide crosslinking agent for a desamino-tyrosyl-tyrosine dipeptide or polypeptides thereof; implantable resorbable medical device; wound healing; the water soluble polymer can also be polysaccharide, polyvinyl alcohol or poly(N-methyl pyrrolidone) |
| 11/06/2008 | US20080274149 Encapsulation and Controlled Release of Biologically Active Ingredients with Enzymatically Degradable Microparticulate, Hyperbranched Polymers |
| 11/06/2008 | US20080274139 Attenuated microorganisms for the treatment of infection |
| 11/06/2008 | US20080274110 Minibodies for use in treatment and prevention of cell proliferative and/or autoimmune disorders |
| 11/06/2008 | US20080274109 Nucleotide sequences coding chemokines for use in dianosis of infection, arteriosclerosis, autoimmune, inflammatory, allergic and arthritic disorders |
| 11/06/2008 | US20080274107 Tyrosine kinase inhibitors |
| 11/06/2008 | US20080274105 Polypeptide variants with altered effector function |
| 11/06/2008 | US20080274101 Stabilizing polypeptides which have been exposed to urea |
| 11/06/2008 | US20080274099 Oncofoetal domain specific immunoglobulin for use in diagnosis, prevention and treatment of cell proliferative disorders |
| 11/06/2008 | US20080274056 Nanoparticle delivery systems for membrane-integrating peptides |
| 11/06/2008 | US20080274045 Imaging, diagnosis and treatment of disease |
| 11/06/2008 | CA2683887A1 Aminodihydrothiazine derivatives substituted with a cyclic group |
| 11/06/2008 | CA2682519A1 Fused heterocyclic derivative, pharmaceutical composition comprising the derivative, and use of the composition for medical purposes |
| 11/05/2008 | EP1988395A1 Methods for evaluating tissue morphogenesis and morphogenic activity |
| 11/05/2008 | EP1988165A1 Isolated DNA encoding cullin regulator ROC1, isolated proteins encoded by the same, and methods utilizing the same |
| 11/05/2008 | EP1988164A1 Method of testing sensitivity of solid cancer against tyrosine kinase inhibitor and test kit therefor |
| 11/05/2008 | EP1988093A1 Bicyclic 6-alkylidene-penems as beta-lactamases inhibitors |
| 11/05/2008 | EP1988077A1 Nirogenous heterocyclic derivatives substituted with cyclic groups |
| 11/05/2008 | EP1988075A1 Pyrrole derivative or salt thereof |
| 11/05/2008 | EP1987844A1 Adhesive patch for external use with improved cohesive force and sustained-release characteristics |